Autolus Limited
12
5
6
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
25.0%
3 terminated/withdrawn out of 12 trials
25.0%
-61.5% vs industry average
0%
0 trials in Phase 3/4
400%
4 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Role: collaborator
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
Role: lead
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Role: lead
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Role: lead
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Role: lead
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Role: lead
Expanded Access Program for OOS Obe-cel
Role: lead
Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus
Role: lead
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Role: lead
Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
Role: lead
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
Role: lead
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
Role: lead
All 12 trials loaded